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Abstract
Proteins which bind methylated lysines (“readers” of the histone code) are important components
in the epigenetic regulation of gene expression and can also modulate other proteins that contain
methyl-lysine such as p53 and Rb. Recognition of methyl-lysine marks by MBT domains leads to
compaction of chromatin and a repressed transcriptional state. Antagonists of MBT domains
would serve as probes to interrogate the functional role of these proteins and initiate the chemical
biology of methyl-lysine readers as a target class. Small molecule MBT antagonists were designed
based on the structure of histone peptide-MBT complexes and their interaction with MBT domains
determined using a chemiluminescent assay and ITC. The ligands discovered antagonize native
histone peptide binding, exhibiting 5-fold stronger binding affinity to L3MBTL1 than its preferred
histone peptide. The first co-crystal structure of a small molecule bound to L3MBTL1 was
determined and provides new insights into binding requirements for further ligand design.
Introduction
Epigenetic mechanisms are the basis for heritable changes in the utilization of the genome in
different cell-types that are not dependent upon changes in the DNA code.1 Epigenetic
regulation during development and differentiation permits the specialization of function
between cells and enables transient environmental factors to result in a lasting change in
cellular and organism behavior.2 Knowledge of the mechanisms and pathways which define
the epigenome holds great promise for our understanding of many domains of biology
including cancer, cell-fate and pluripotency.3
The substrate for epigenetic control is chromatin – the complex of DNA, RNA and histone
proteins that efficiently package the genome in an appropriately accessible form within each
cell. The building block of chromatin structure is the nucleosome: an octamer of histone
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proteins – associated dimers of H3 and H4 capped with dimers of H2A and H2B – around
which 147 base pairs of DNA are wound. The amino-terminal tails of histone proteins are
unstructured and protrude from the nucleosomes where they are subject to more than 100
posttranslational modifications.4 These modifications are referred to as the histone code and
include histone lysine and arginine methylation; lysine acetylation, DNA cytosine
methylation and histone sumoylation, ubiquitination, ADP-ribosylation and
phosphorylation. These covalent modifications often serve to create docking sites for
proteins that directly or indirectly modulate RNA polymerase activity. Among these, the
methylation of lysine residues plays a central role through its influence on the activation and
repression of gene expression. The enzymatic components of lysine methylation have been
targeted for chemical probe and drug discovery and are well documented5 and a recent
report has highlighted antagonists of readers of acetyl-lysine.6 However, experimental
reports of small molecule inhibitors of methyl-lysine binding proteins, readers of the histone
code, are limited.7,8
Malignant Brain Tumor (MBT) domains belong to an extended family of methyl-lysine
binding proteins which is referred to as the ‘Royal family’, made up of Tudor, Agenet,
chromo, PWWP, the WD40 repeat protein and the plant homeodomain (PHD). Current
estimates of the number of methyl-lysine binding modules in the human proteome is >170
and there is no doubt that this estimate will grow over time.9 A recent review of the
available high-resolution crystal structures of these domains summarizes the key recognition
features as an electron-rich aromatic cage binding the methyl-lysine cation with additional
charge neutralization and H-bonding to up to two acidic functionalities, depending upon the
methylation state of the binder (Figure 1A).10 The ability of this rather subtle chemical
modification, which results in no change in charge of the modified residue, to selectively
mediate protein-protein interactions that profoundly regulate gene expression is rather
remarkable.
MBT domains selectively recognize lower methylation states (KMe1, KMe2) of histone
lysine residues and their binding leads to compaction of chromatin and overall repression of
gene expression.11 The crystal structures of multiple MBT domains have been solved and
reveal few specific interactions beyond the methylated lysine of the histone peptides co-
crystallized in these studies12 suggesting that in contrast to PHD fingers, chromo and tudor
domains, very little sequence specificity can be anticipated. The lack of sequence specificity
for L3MBTL1 is also evident in binding affinities of dye tagged peptides containing mono
or dimethyl-lysine determined using fluorescence polarization (FP) assays.12a, 13 For our
research aimed at discovery of small molecule MBT ligands, we selected a representative
subset of proteins from the MBT family. We chose L3MBTL1, a member of the MBT
family having a tandem repeat of three MBT domains, as our primary target based on the
availability of structural and biological data.13-14 L3MBTL1 is known to act as a “chromatin
lock”14a to repress expression of E2F regulated genes such as the growth related and
oncogenic c-myc gene. Recently, L3MBTL1 has also been shown to bind to the tumor
suppressor p53 via methylation dependent recognition of lysine 382 and indeed, it has been
suggested that repression of c-myc may also be mediated via binding to lysine-methylated
retinoblastoma (Rb) protein15 which is methylated by SMYD2.16 Furthermore, depletion of
L3MBTL1 has been linked to both DNA breaks, the DNA replication machinery and
ultimately genomic instability.17 Therefore, L3MBTL1 appears to be directly implicated in
the stability of DNA and the reader functions as both a reader of repressive lysine
methylation marks on histones and the methylation status of key regulatory proteins to
integrate chromatin availability with the activity and location of these proteins. From a
structural biology perspective it is noteworthy that only the second MBT domain of
L3MBTL1 has been shown to bind methyl-lysine and the function of the remaining MBT
domains is not understood, though it has been suggested that they play a role in recognition
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of multiple nucleosomes or residues other than methyl-lysine.15 In addition, L3MBTL1 has
been shown to be involved in the erythroid differentiation of human hematopoietic
progenitor cells.18
To make up our initial methyl-lysine target-class panel we selected homologues of
L3MBTL1: L3MBTL319 and L3MBTL420 and to cover the other branches of the
phylogenetic tree, SFMBT121 and MBTD1 (Figure 1B).22 To gauge selectivity versus other
methyl-lysine binding domains, the PHD finger PHF13 which has been shown to bind di-
and trimethylated lysine23 and the chromo domain CBX7 were chosen.24 While this panel of
methyl-lysine binding domains only scratches the surface of this large target-class, inclusion
of both closely related MBT domains and more distant and structurally diverse binders
provides an initial basis to assess both the selectivity of ligands and the tractability of
binders for ligand discovery. Several previous publications report modest binding constants
(Kd’s in the micromolar range) of various peptides to L3MBTL1 and we anticipated
challenges in both assay development and the discovery of potent ligands.
To circumvent this affinity problem, we developed a high-throughput assay suitable for
discovery of weak antagonists of peptide binding using an Amplified Luminescent
Proximity Homogeneous Assay (AlphaScreen) technology.25 This bead-based
chemiluminescent platform is suited for low-affinity interactions as binding is artificially
enhanced due to the avidity of the multiple binding sites on each bead. During this research
and a subsequent high throughput screen of a 100,000 member diversity library, we were
unable to identify tractable hits that retained activity in isothermal titration calorimetry
(ITC) experiments and we were therefore motivated to focus our efforts on the ligand and
structure-based hit discovery effort described here. We have also applied virtual screening to
ligand discovery for L3MBTL1 and those results were recently published.7
Results and Discussion
Peptidomimetics
For our initial exploration of antagonists of MBT domains we chose to maintain a peptide-
like structure modeled on the published co-crystal structure of H4K20Me2 bound to
L3MBTL1.12b Based on the weak binding and lack of specific interactions with native
sequences, our design only included two amino-acids: a histidine residue intended to make
an interaction with threonine 385 on the protein surface (Figure 1), and for ease of
purification a phenylalanine residue in place of arginine. The key methylated lysine residue
was replaced with a variety of simple diamines (Table 1) as no interactions with more
carboxy terminal portions of H4K20Me1 were anticipated.
In the AlphaScreen assay both methylethylamine 5 and pyrrolidine 6 (Table 1) had better
binding affinities to MBT domains compared to the mono and dimethyl-lysine
modifications, however some interference with the assay signal was also noted for these
compounds in the previously described counterscreen.25a This interference was also
observed with a subset of small-molecule scaffolds. The binding of select antagonists
identified in the homogeneous chemiluminescent assay were therefore confirmed using
ITC.26 ITC offers a direct and complete characterization of the thermodynamic properties
and stoichiometry involved in a bimolecular equilibrium interaction,27 in which the ligand
(small molecule) is titrated into the receptor (protein). The obvious disadvantage of ITC is
the use of large amounts of protein. Consistent with a specific interaction with the methyl-
lysine binding site of L3MBTL1, ITC confirmed the expected effect of lysine methylation
state on binding in our antagonists: unmethylated amines and quaternary ammonium species
(1 and 4) did not bind while mono- and dimethylated amines 2 and 3 bound weakly (Kd >
100 μM). Pyrrolidine analog 6 showed significantly higher binding affinity relative to the
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mono- and dimethylated amines. The ITC data also confirmed the 1:1 stoichiometry of
binding between all of the peptidomimetics and the MBT domain. To further confirm that
the binding of the peptidomimetics occurred at the anticipated site in MBT domain 2 of
L3MBTL1, we expressed the D355A mutant of L3MBTL1 in which the critical aspartic acid
residue in this binding pocket is replaced by an alanine thereby eliminating the ability to
form a salt bridge to the methylated lysine or lysine mimetic.12b, 14a Indeed, no binding was
observed between compound 6 and D355A L3MBTL1 by ITC (Figure 2B).
Small-Molecule Ligands of MBT Domains
To further explore MBT ligand requirements and based on the seeming lack of influence of
neighboring residues in a peptide context, we extended our studies toward nonpeptidic small
molecules. We were particularly interested in whether pyrrolidine mimics of the methyl-
lysine side chain could provide affinity in the context of simple aromatic anchors with good
predicted cell permeability that could easily be modified using standard chemical methods.
Such scaffolds could also improve the ligand efficiency significantly.28
Indeed, simple aromatic anchors with pyrrolidinyl side-chains (7 (UNC280), Figure 3A)
interacted with MBT domains in the AlphaScreen without interference in the counterscreen
(Table 3).25a Binding was confirmed using ITC for both L3MBTL1 (Table 4) and
L3MBTL3 (data not shown). In the context of work with small molecules it was found that
the presence of DMSO in ITC experiments abolished all binding and ITC experiments were
therefore performed using aqueous buffer for dissolution. The nicotinic acid-based
pyrrolidine, 7 binds with a Kd of 26 μM to L3MBTL1 and represents a significant
improvement in ligand efficiency28 compared to the native H4K20Me1 9-mer peptide
(residues 17-25, Kd = 24 ± 1 μM). The calculated ligand efficiencies for both the 9-mer
peptide12b and the small molecule ligand 7 using the pKd data available from ITC assays
indicate a 4-fold increase in binding efficiency. For context, we also tested mono- and
dimethyl-lysine via ITC and both exhibit binding constants exceeding 250 μM against
L3MBTL1.
Our recently reported virtual screen6 of L3MBTL1 also selected a pyrrolidine containing
sulfonamide of similar potency to 7 and further optimization was based on both
arylsulfonamide and nicotinic acid scaffolds.
In hopes of developing SAR for these scaffolds and enhancing potency, greater than 350
compounds were synthesized and tested in the AlphaScreen format. For example, Suzuki
couplings to replace the aryl bromide of 7 with aromatic groups and various aromatic
anchors were tested in order to potentially discover a favorable interaction outside the
methyl-lysine binding pocket. Unfortunately, the resulting structure-activity relationships
(SAR) were flat and demonstrated that for larger substituents any additional enthalpy (ΔH)
gain was negated by increasing entropic penalties resulting in diminished overall binding
affinity (data not shown).
The most promising results emerged from our study of the effect of the aliphatic sidechain
and the nature of the amine. This was anticipated as the most important contributions to
binding arise from the insertion of lysine mimetics into the binding cavity and interactions
with the aromatic pocket and the acidic residue D355. In the sulfonamide series, β-
oxygenated amines either within the aliphatic side chain (8) or the amine (morpholine 9) did
not show any activity consistent with the importance of a very basic amine for effective
binding to MBT domains (Table 2).
Analogues with methylation of the 2- and 3-position of the pyrrolidine (11 and 12) weaken
the binding affinity significantly whereas a 3-methyl group abolishes all binding. However,
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fluorination at the 3-position of the pyrrolidine is permitted (2-fold weaker). Further study of
the aliphatic linker did not reveal any effect of the length of the chain, however, most
restricted, bulky or aromatic linkers failed to bind to the selected MBT domains. An
exception was 14 (UNC669) which exhibited a promising 6 μM binding affinity in the
chemiluminescent assay.
The results of profiling conformationally less constrained 7 and more constrained 14 versus
our panel of methyl-lysine binding domains are summarized in Table 3. Whereas 7 shows
weak binding in the AlphaScreen against L3MBTL1, L3MBTL3 and PHF13, 14 is 5-fold
selective for L3MBTL1 over L3MBTL3, 10-fold selective over L3MBTL4 and does not
interact with the other domains.
Based on promising results in the chemiluminescent assay, 14 was selected for ITC
experiments and strong binding to L3MBTL1 of 5 ± 1 μM was confirmed (Table 4).
Compared to the native peptide H4K20Me1, this is a 5-fold increase in binding affinity and
an almost 5-fold increase in ligand efficiency.28 Analogous to 7, 14 demonstrated no
binding to the D355A mutant of L3MBTL1 (Figure 4A). Together with the ITC-based one-
site binding in the wild-type protein, these results suggest that 14 only interacts with
L3MBTL1 in the intended binding pocket in the second MBT subdomain of the protein.
Finally, to demonstrate histone peptide antagonism with 14, we utilized an FP assay12a, 13, 29
employing the same H3K9Me1 peptide that was utilized in our AlphaScreen assay. Indeed,
nicotinamide 14 competes with the FAM-labeled peptide effectively with a  of 10 ± 0.4
μM consistent with both the AlphaScreen and ITC results (Figure 4C).
To further characterize the binding interaction of our most potent ligand with L3MBTL1 and
provide a firm structural basis for future directions in probe optimization, a co-crystal
structure of L3MBTL1 (residues 200-522 comprising the three MBT repeat) in complex
with nicotinamide 14 was obtained at 2.55 Å resolution. Consistent with our mutagenesis
studies, structural analysis confirmed the binding of 14 in the methyl-lysine recognition site
located in the second MBT module of the protein (Figure 4B). The structure further
highlights a binding mode in which the conformationally rigid aliphatic side chain of the
ligand inserts into the hydrophobic cage which contains the essential residue D355. The
pyrrolidinyl ring adopts an orientation which results in a 2.6 Å separation between the amine
and D355, providing a rich mixture of hydrogen bonding, salt bridge and hydrophobic
interactions (from ring carbons). Furthermore, the proximity of the amine to key aromatic
residues Y386, W382 and F379 in the hydrophobic cage results in additional π-cation
interactions. While the ligand lacks other polar interactions with the protein, including a
mostly solvent-exposed bromo-nicotinamide anchor, good shape complementarity with the
binding pocket gained through the presence of a bulky side chain contributes additional van
der Waals interactions towards ligand binding. Of note is the coplanarity of the piperidine
moiety and W382. Comparison with the H4K20Me2 structure (Supporting Information)
shows that although the orientation of the amine is similar to 14, the less bulky lysine side
chain and presence of other non-productive residues results in reduced potency and ligand
efficiency for the peptide.
Conclusion
By using a ligand- and structure-based design approach we were able to significantly
improve the potency of initial MBT domain hits and determine the first small molecule
methyl-lysine binding domain co-crystal structure. While the AlphaScreen technology was
useful as a high-throughput assay for discovery and profiling of low affinity hits, ITC was
required to develop SAR, confirm and fully characterize small molecule binders of these
proteins. Starting with the identification of increased affinities of pyrroldinyl scaffolds, we
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discovered the conformationally rigid analogue 14 as a low μM binder of L3MBTL1,
exhibiting 5-fold greater affinity than the cognate peptide H4K20Me1 and a significantly
improved ligand efficiency. Furthermore, 14 is 6-fold selective for L3MBTL1 over its close
homolog L3MBTL3 and 10-fold selective over L3MBTL4. Our studies indicate that MBT
domains can accommodate larger amines than just mono- and dimethylamines such as
pyrrolidines, but that the size of the binding pocket does not allow for methyl substituted
pyrrolidine. Further analysis of the co-crystal structure of 14 with L3MBTL1 will provide
new directions for further chemistry to improve potency and selectivity. The small molecule
binders of MBT domains described are expected to be cell-penetrant and future efforts will
also be directed toward functional and cell-based studies to progress toward a high quality
chemical probe of these readers of the histone code.30
METHODS
Synthesis
Detailed synthetic procedures and characterizations are described in Supporting Information.
Protein Purification
L3MBTL1 was expressed and purified as described.25a Briefly, cell pellets from a 2 L
culture expressing His-tagged L3MBTL1 were lysed with BugBuster protein extraction
reagent (EMD Chemicals, Gibbstown, NJ) containing 20 mM imidazole. The cell lysate was
clarified by centrifugation and loaded onto a 5 mL HisTrap HP column (GE Healthcare,
Piscataway, NJ) equilibrated with binding and wash buffer (50 mM sodium phosphate buffer
pH 7.2, 500 mM NaCl, 20 mM imidazole) using an ÄKTA FPLC (GE Healthcare,
Piscataway, NJ) at 1 mL/min. His-tagged L3MBTL1 was eluted using a linear gradient of
elution buffer (50 mM sodium phosphate buffer pH 7.2, 500 mM NaCl, 500 mM imidazole)
over 20 column volumes. Fractions containing L3MBTL1 were confirmed by SDS-PAGE,
pooled and loaded at 2 ml/min onto a HiLoad 26/60 Superdex 200 preparative grade size
exclusion column (GE Healthcare, Piscataway, NJ) using an ÄKTA FPLC. A constant flow
of 2 ml/min size exclusion buffer (10 mM Tris·HCl pH 8.0, 300 mM NaCl, 1 mM EDTA, 2
mM DTT, 0.02% Tween 20) was used to elute L3MBTL1. Fractions containing L3MBTL1
were identified by SDS-PAGE, pooled and subjected to simultaneous concentration and
buffer exchange using an Amicon Ultra-15 centrifugal filter unit (Millipore, Billerica, MA)
and storage buffer (20 mM Tris·HCl pH 8.0, 150 mM NaCl and 2 mM DTT). Protein
concentration was determined by Bradford assay and protein purity was determined to by
>95% by Coomassie.
The D355A mutant of L3MBTL1 was obtained from the SGC in Toronto and expressed and
purified analogously to the wt L3MBTL1.
ITC Experiments
For the ITC measurements, L3MBTL1 was extensively dialyzed into ITC buffer (20 mM
Tris-HCl, pH 8, 25 mM NaCl and 2 mM β-mercaptoethanol. Subsequently, the
concentration was established using the Edelhoch method.31 The ITC experiments were
performed at 25 °C, using an AutoITC200 microcalorimeter (GE MicroCal Inc., USA).
Experiments were performed by injecting 1.5 μl of 1 mM solution of the compounds into a
200 μL sample cell containing 50 μM L3MBTL1. A total of 26 injections were performed
with a spacing of 180 seconds and a reference power of 8 μcal/s. Compounds were dissolved
in ITC buffer at 10 mM and diluted to 1 mM. A control experiment for each compound was
also performed and the heat of dilution was measured by titrating each compound into buffer
alone. The heat of dilution generated by the compounds was subtracted, and the binding
isotherms were plotted and analyzed using Origin Software (MicroCal Inc., USA). The ITC
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measurements were fit to a one-site binding model. The ITC experiments using the D355A
mutant of L3MBTL1 were performed analogously to the above mentioned procedure.
Fluorescence polarization displacement assay
A histone peptide consisting of residues 1-15 of the H3 histone tail containing an N-terminal
fluorescein, a 6-aminohexanoic acid linker, and monomethyl lysine at position 9 (FAM-
H3K9Me1)12a, 13 was used as the fluorescent probe to bind L3MBTL1 in the FP
displacement assay (FAM-AHA-ARTKQTARK(Me)STGGKA-CO2H). Binding assays
were carried out in 20 mM Tris-HCl (pH 8.), 25 mM NaCl, and 2 mM β-mercaptoethanol in
black 384-well microplates (Corning, non-binding surface) with a final volume of 30 μL per
well. To each well, 20 μL of a 150 nM stock solution of H3 FAM-K9Me was added to give
a final concentration of 100 nM, followed by 5 μL of a 120 μM stock solution of L3MBTL1
to give a final protein concentration of 20 μM. Serial dilutions were prepared of inhibitor
UNC669 (14) and added (5 μL) to give a final concentration range of 0-400 μM. Plates were
incubated for 20 min at room temperature prior to analysis. FP measurements (mP) were
made on an AcQuest (LJL BioSystems) plate reader at room temperature, with an excitation
wavelength of 485 nm and the emission collected at 530 nm. The G factor was determined
to be 0.92 from a standard solution of fluorescein and corrected for by the instrument
software. All measurements were made in triplicate with 10 readings collected in each
measurement.
Crystallization, data collection and structure determination
Purified protein was obtained using methods established previously for the three-MBT
repeat (3MBT) domain of human L3MBTL1 (residues 200-522).12b Crystallization was
performed using a protein sample concentrated to 10 mg/mL and pre-incubated with 1 mM
compound 14 (UNC669). Initial screening was carried out by sitting drop vapor diffusion at
room temperature using an in-house sparse-matrix crystallization screen, yielding needles
which appeared after four days in a condition containing 25% PEG 3350, 0.1 M ammonium
sulfate, and 0.1 M Bis-Tris buffer pH 5.5. The crystals belong to the trigonal space group
P32 with unit cell dimensions of a = b = 106.3 Å, and c = 90.1 Å, containing three molecules
in the asymmetric unit. A single crystal was cryoprotected by soaking in well solution with
18% glycerol (v/v) for 60 s before flash freezing in liquid nitrogen.
Diffraction data were collected at 100 °K using synchrotron radiation at the Canadian
Macromolecular Crystallography Facility (CMCF) on beamline 08ID-1 at the Canadian
Light Source (Saskatoon, SK, Canada). Intensities were integrated and scaled using
HKL2000.32 The structure of 3MBT/UNC669 complex was solved by the molecular
replacement method as implemented by MOLREP in the CCP4 program suite33 using the
structure of human 3MBT domain in complex with 2-(N-morpholino)ethanesulfonic acid
(MES) (PDB 2RJC) as a search model. Following alternate cycles of restrained refinement
and manual model rebuilding using COOT,34 the improved model revealed clear electron
density allowing unambiguous placement of the bound ligand 14 (UNC669) in the methyl-
lysine binding site of two of three protein chains. The inhibitor was not modeled in the third
chain (chain C) owing to poorly defined electron density. All refinement steps were
performed using REFMAC35 in the CCP4 program suite. The final model comprising three
molecules of 3MBT domain, two molecules of UNC669, and solvent molecules including
glycerol and sulfate molecules refined to an Rwork of 19.1% and Rfree of 24.2%. Data
collection and structure refinement statistics are summarized in the Supporting Information
(SI, Table 1). Structure figures were prepared using PyMOL.36 Atomic coordinates and
structure factors for 3MBT/UNC669 complex have been deposited in the Protein Data Bank
with accession code 3P8H.
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Rb retinoblastoma protein
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H4K20Me1 histone H4 lysine 20 monomethyl
E2F E2 transcription factor
SMYD2 SET and MYND domain-containing protein 2
SFMBT1 SCM-related gene containing four MBT domains
MBTD1 MBT domain containing 1
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A) Histone peptide showing the methylated lysine and presumed interactions with
L3MBTL1 based on the H4K20Me2-L3MBTL1 co-crystal structure. B) Phylogenetic tree of
human proteins containing MBT domains; other protein subdomains are omitted for clarity.
Protein names in red signifies an assay described in the paper.
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A) Effect of methylation state on binding of 1, 4 and 6 to L3MBTL1. B) ITC binding curves
for pyrrolidinyl analog 6 with both wt L3MBTL1 and D355A mutant of L3MBTL1.
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A) ITC binding curve of nicotinamide (7) to both wt L3MBTL1 and D355A mutant. B)
Docking of 7 to L3MBTL1, illustrating the solvent exposure of aromatic anchor.
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A) ITC binding curve of 14 to wt L3MBTL1 overlayed with the titration using the D355A
mutant of L3MBTL1. B) Co-crystal structure of 14 with L3MBTL1. C) Binding curve for
14 in a FP displacement assay with FAM-H3K9Me1.
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Table 1




1 No interaction observed
2 >100
3 >100
4 No interaction observed
5 78 ± 9

















6 37 ± 1
a
Kd values are the average of two independent trials, ± the standard deviation.
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Table 2




8 No Binding a
9 No Binding a
10 25 ± 8
11 >100
12 No BindingInteraction
13 51 ± 9
a
No binding by AlphaScreen.
b
Kd values are obtained from single experiments, standard deviations result from least square curve fitting.
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Table 4
Thermodynamic binding parameters of nicotinamides 7 and 14 to L3MBTL1 using ITC.
Compound Kd μM ΔH kcal/mol TΔS kcal/mol
26 ± 0.7 −15 ± 0.4 −9 ± 0.4
5 ± 1 −13 ± 0.6 −6 ± 0.5
a
Values are the average of at least two independent trials ± the standard deviation.
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